HBSS, Modified (Without Ca++ and Mg++)

Hanks' Balanced Salt Solution (HBSS) without calcium and magnesium

More Views

HBSS, Modified (Without Ca++ and Mg++)

Hanks' Balanced Salt Solution (HBSS) without calcium and magnesium

500 mL
Catalog #37250
32 USD

.

Overview

Hanks’ Balanced Salt Solution (HBSS) can be used for diluting, washing, irrigating, or as a transporting solution for cell or tissue culture. It provides a buffering system to maintain the physiological pH range and osmotic balance of culture media, and provides cells with a source of water and essential inorganic ions, and a carbohydrate as an energy source. Selection of suitable nutrient medium is dependent on type of cell, culture conditions, and degree of chemical definition required for the cell culture application.
Contains:
• Phenol red
• Other ingredients

Technical Resources

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Journal of controlled release : official journal of the Controlled Release Society 2011 MAR

Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.

Thomas AM et al.

Abstract

5-Fluorouracil (5-FU) is a small, very membrane permeable drug that is poorly retained within the aqueous compartment of liposomal nanoparticles (LNP). To address this problem a novel method relying on formation of a ternary complex comprising copper, low molecular weight polyethylenimine (PEI) and 5-FU has been developed. More specifically, in the presence of entrapped copper and PEI, externally added 5-FU can be efficiently encapsulated (textgreater95%) in DSPC/Chol (1,2-Distearoyl-sn-Glycero-3-Phosphocholine/cholesterol; 55:45 mol%) liposomes (130-170 nm) to achieve drug-to-lipid ratios of 0.1 (mol:mol). Drug release studies completed using this LNP formulation of 5-FU demonstrated significant improvements in drug retention in vitro and in vivo. Plasma concentrations of 5-FU were 7- to 23-fold higher when the drug was administered intravenously to mice as the LNP 5-FU formulation compared to free 5-FU. Further, the therapeutic effects of the LNP 5-FU formulation, as determined in a HT-29 subcutaneous colorectal cancer model where treatment was given QDx5, was greater than that which could be achieved with free 5-FU when compared at equivalent doses. This is the first time an active loading method has been described for 5-FU. The use of ternary metal complexation strategy to encapsulate therapeutic agents may define a unique platform for preparation of LNP drug formulations.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
Chat with an Expert